Bosentan Dosing in Newborns
For newborns weighing less than 10 kg, the recommended bosentan dose is 2 mg/kg orally twice daily, starting at half this maintenance dose (1 mg/kg twice daily) and uptitrating as tolerated. 1
Weight-Based Dosing Algorithm
According to the 2015 AHA/ATS Pediatric Pulmonary Hypertension Guidelines, bosentan dosing follows a strict weight-based protocol 1:
- Weight <10 kg (typical newborn range): 2 mg/kg twice daily orally
- Weight 10-20 kg: 31.25 mg twice daily
- Weight 20-40 kg: 62.5 mg twice daily
- Weight >40 kg: 125 mg twice daily
Critical caveat: Always start at half the maintenance dose and uptitrate. This means for a newborn <10 kg, initiate at 1 mg/kg twice daily, then increase to the full 2 mg/kg twice daily dose as tolerated.
Evidence Quality and Clinical Context
The guideline recommendation carries a Class I indication with Level of Evidence B 1. This represents strong evidence supporting bosentan use in pediatric pulmonary hypertension, though the newborn population specifically has more limited data.
Research Evidence Shows Mixed Results
The most rigorous trial (FUTURE-4,2016) was a randomized placebo-controlled study in neonates with persistent pulmonary hypertension (PPHN) using 2 mg/kg twice daily 2. While bosentan was well-tolerated, it did not improve oxygenation or time to wean from inhaled nitric oxide. Importantly, blood concentrations were low and variable on day 1, only reaching steady state by day 5, suggesting delayed absorption in critically ill neonates may limit early efficacy 2.
However, multiple observational studies show more promising results:
- A 2012 randomized trial showed 87.5% favorable response versus 20% with placebo 3
- A 2018 retrospective series of 40 neonates demonstrated significant improvement in oxygenation within 2 hours 4
- A 2025 case series of 50 CDH neonates showed 54% improved pulmonary hypertension within one week 5
Safety Monitoring Requirements
Monthly liver function tests are mandatory due to hepatotoxicity risk, though the incidence of AST/ALT elevation is lower in children compared to adults 1. Additional monitoring includes:
- Fluid retention assessment
- Systemic blood pressure (bosentan did not adversely affect BP in neonatal studies 2)
- Anemia and edema (more frequent in neonates receiving bosentan 2)
Clinical Pitfalls to Avoid
Do not expect immediate effect: Pharmacokinetic data shows delayed absorption with low, variable concentrations initially 2. Clinical improvement may take 2-7 days 5, 4.
Consider combination therapy for non-responders: When bosentan alone is insufficient, adding sildenafil has shown superior outcomes, with combination therapy more effective at reducing pulmonary artery pressures than sildenafil monotherapy 6.
Drug interaction alert: Bosentan has documented interactions with sildenafil 1, though combination therapy is commonly used and generally safe 6.
Route of administration matters: Bosentan must be given enterally via nasogastric tube in intubated neonates. Ensure adequate enteral access and absorption capacity before initiating 2.
When to Use Bosentan in Newborns
Bosentan is indicated as adjunctive therapy for neonates with:
- PPHN requiring inhaled nitric oxide (≥4 hours) with persistent respiratory failure (oxygenation index ≥12) 2
- CDH-associated pulmonary hypertension 5
- Congenital heart disease with pulmonary hypertension 7
Bosentan can be used as monotherapy in mild-to-moderate PPHN or as adjunctive therapy with inhaled nitric oxide in severe cases 4.